2023•SSRN Electronic JournalOpen access

Immunogenicity, Reactogenicity and Safety of a Second Booster with BNT162b2 or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1-AGED Part B)

Jannik Stemler, Lusine Yeghiazaryan, Christoph Stephan, Kirsten Greve-Isdahl Mohn, Antonio J. Carcas, Esperanza Romero Rodriguez, José Marhuenda Moltó, Itziar Vergara Micheltorena, Tobias Welte, Birutė Zablockienė, Murat Akova, Ullrich Bethe, Sarah Heringer, Jon Salmanton‐García, Julia Jeck, Lea Tischmann, Marouan Zarrouk, Arnd Cüppers, Lena M. Biehl, Jan Hendrik Grothe, Sibylle C. Mellinghoff, Julia Alexandra Nacov, Julia Neuhann, Rosanne Sprute, Jesus A Frias, Riya Negi, Colette Gaillard, Gurvin Saini, Alejandro Abner Garcia Leon, Patrick W. G. Mallon, Christine Lammens, An Hotterbeekx, Katherine Loens, Surbhi Malhotra‐Kumar, Herman Goossens, Samir Kumar‐Singh, Franz König, Martin Posch, Philipp A. Koehler, Oliver A. Cornely

Open full text 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Reactogenicity, Booster (rocketry), Immunogenicity, Medicine, Booster dose, Pediatrics, Immunology, Engineering